Difference between revisions of "Entospletinib (GS-9973)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "9 PubMed" to "9/ PubMed") |
||
Line 5: | Line 5: | ||
===[[Chronic lymphocytic leukemia]]=== | ===[[Chronic lymphocytic leukemia]]=== | ||
− | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/25696919 PubMed] | + | # Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. [http://www.bloodjournal.org/content/125/15/2336.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/25696919/ PubMed] |
==Also known as== | ==Also known as== |
Revision as of 00:13, 7 May 2023
Mechanism of action
Spleen tyrosine kinase (SYK) inhibitor
Preliminary data
Chronic lymphocytic leukemia
- Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article PubMed
Also known as
- Code name: GS-9973